Contact Us |








dayanews emp nodaya


22 | July | 2014

Pluristem to Host Investor Breakfast and Webcast on July 23 in New York City

Read more >

08 | July | 2014

Pluristem Initiates South Korean Arm of Multinational Phase II Intermittent Claudication Trial

Read more >

30 | June | 2014

Pluristem’s Ohad Karnieli to Deliver a Plenary Presentation on Cell Therapy Manufacturing at ISUS 2014 Conference

Read more >

25 | June | 2014

Pluristem Selects Rotator Cuff Repair as New Orthopedic Indication

Read more >

About hp

Zami Aberman

Chairman and CEO


Zami Aberman

   From the CEO

I would like to respectfully recognize this month of May as preeclampsia month. In 2012, Representatives Lucille Roybal-Allard (CA-34), Lois Capps (CA- 23), and Gwen Moore (WI-4) were successful in their request that the US Dept. of Health & Human Services designate May as National Preeclampsia Awareness Month. Recently, Governor Chris Christie issued a proclamation declaring May 2014 Preeclampsia Awareness Month in the State of New Jersey. I cheer the efforts of these legislators to raise awareness for a potentially lethal disorder for which there is no treatment. It leaves the mother with a significantly higher risk of high blood pressure and stroke in later years, while potentially harming a baby’s health and development in the case of premature delivery. 

I believe Dr. Baha M. Sibai of the University of Texas, a recognized leader in preeclampsia and Chair of Pluristem’s Preeclampsia Steering Committee, put it best when he stated, “For almost a thousand years, physicians have had no therapy to offer women with preeclampsia. A safe and effective therapy is needed to treat these women and prolong gestation.”

This tremendous unmet medical need makes this indication one of our top priorities at Pluristem and we will be proud to advance our novel PLX-PAD cell therapy product into the clinic. We are hopeful that the very strong preclinical data we have accumulated using PLX-PAD in preeclampsia will translate into similar results at the clinical level.

   Zami Aberman

   Chairman and CEO 


Share Button comm

Investors hp

     Yaky Yanay
     President and COO


Yaky Yanay

Pluristem's wholly owned subsidiary, Pluristem Ltd., has received approval for a 14.6 million New Israeli Shekel (approximately $ 4.2 million) grant from the Office of the Chief Scientist (OCS) within the Israeli Ministry of Economy. Once received, the grant will be used to cover R&D expenses for the period January 2014 to December 2014.


Read more >> 

Share Button comm

tech hp

Ohad Karnieli, Ph.D., MBA
VP Development & Manufacturing


Ohad Karnieli

The United States Food and Drug Administration (FDA) has reviewed Pluristem’s comparability studies of its PLacental eXpanded (PLX) cell products and granted approval for the Company to manufacture these products in its new commercial-scale cell manufacturing facility.



Share Button comm

Clinical Program hp

Esther Lukasiewicz Hagai, M.D., Ph.D.
VP Clinical & Medical Affairs


Esther Lukasiewicz Hagai

Medical Key Opinion Leaders in Preeclampsia Join Pluristem’s Steering Committee:

Prof. James M. Roberts, M.D., University of Pittsburgh
Professor, Department of Obstetrics, Gynecology and Reproductive Sciences
Professor of Epidemiology, Senior Scientist, Magee-Women’s Research Institute

Prof. George R. Saade, M.D., University of Texas Medical Branch
Professor, Division Chief Obstetrics & Gynecology

Prof. Baha M. Sibai, M.D., University of Texas Medical School, Visiting Professor

Dr. David Williams, PhD FRCP, University College London
Honorary Senior Lecturer, Maternal & Fetal Medicine, Institute for Women's Health, Faculty of Population Health Sciences

Prof. Simcha Yagel, M.D., Hadassah Medical Center, Israel
Head Division of Obstetrics and Gynecology at Hadassah Medical Center
Head of the Israeli Association of Placental Study



Share Button comm


 catom 01

catom 03

catom 05

catom 07

catom 09

catom 11

catom 13




catom 02

Share Button